Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain

References

• DworkinRHO’ConnorABKentJInternational Association for the Study of Pain Neuropathic Pain Special Interest Group. Interventional management of neuropathic pain: NeuPSIG recommendationsPain20131542249226123748119
   PubMed Web of Science ®Google Scholar
• AttalNCruccuGBaronREuropean Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEur J Neurol2010171113e118820402746
   PubMed Web of Science ®Google Scholar
• BarrettAMLuceroMALeTRobinsonRLDworkinRHChappellASEpidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a reviewPain Med20078Suppl 2S50S6217714116
   PubMed Web of Science ®Google Scholar
• SmithBHTorranceNEpidemiology of neuropathic pain and its impact on quality of lifeCurr Pain Headache Rep20121619119822395856
   PubMed Web of Science ®Google Scholar
• BerezaBGMachadoMRavindranAVEinarsonTREvidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorderCan J Psychiatry20125747047822854029
   PubMed Web of Science ®Google Scholar
• ParmentierHGarcía-CampayoJPrietoRComprehensive review of generalized anxiety disorder in primary care in EuropeCurr Med Res Opin20132935536723356728
   PubMed Web of Science ®Google Scholar
• CombsHMarkmanJAnxiety Disorders in Primary CareMed Clin North Am2014981007102325134870
   PubMed Web of Science ®Google Scholar
• WeisbergRBOverview of generalized anxiety disorder: epidemiology, presentation, and courseJ Clin Psychiatry200970Suppl 24919371500
   PubMed Web of Science ®Google Scholar
• DothAHHanssonPTJensenMPTaylorRSThe burden of neuropathic pain: a systematic review and meta-analysis of health utilitiesPain201014933834420227832
   PubMed Web of Science ®Google Scholar
• HoffmanDLDukesEMWittchenHUHuman and economic burden of generalized anxiety disorderDepress Anxiety200825729017146763
   PubMed Web of Science ®Google Scholar
• TurkDCAudetteJLevyRMMackeySCStanosSAssessment and treatment of psychosocial comorbidities in patients with neuropathic painMayo Clin Proc201085Suppl 3S42S5020194148
   PubMed Web of Science ®Google Scholar
• HenningERTurkCLMenninDSFrescoDMHeimbergRGImpairment and quality of life in individuals with generalized anxiety disorderDepress Anxiety20072434234917091478
   PubMed Web of Science ®Google Scholar
• UntereckerSProftFRiedererPLauerMDeckertJPfuhlmannBThe comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysisTher Drug Monit20143626927224365982
   PubMed Web of Science ®Google Scholar
• MalyJDosedelMKubenaAVlcekJAnalysis of pharmacists’ opinions, attitudes and experiences with generic drugs and generic substitution in the Czech RepublicActa Pol Pharm20137092393124147373
   PubMed Web of Science ®Google Scholar
• CorraoGSorannaDLa VecchiaCMedication persistence and the use of generic and brand-name blood pressure-lowering agentsJ Hypertens20143211461153 discussion 115324569417
   PubMed Web of Science ®Google Scholar
• ChenHYChangHRLangHCEffects of hospital generic drug substitution on diabetes therapyPatient Prefer Adherence2014812713324511228
   PubMed Web of Science ®Google Scholar
• OlesenCHarbigPBaratIDamsgaardEMGeneric substitution does not seem to affect adherence negatively in elderly polypharmacy patientsPharmacoepidemiol Drug Saf2013221093109824038668
   PubMed Web of Science ®Google Scholar
• CandidoKDChiwesheJAnantamongkolUKnezevicNNCan chronic pain patients be adequately treated using generic pain medications to the exclusion of brand-name ones?Am J Ther8262014 Epub ahead of print
   Web of Science ®Google Scholar
• GagneJJChoudhryNKKesselheimASComparative effectiveness of generic and brand-name statins on patient outcomes: a cohort studyAnn Intern Med201416140040725222387
   PubMed Web of Science ®Google Scholar
• Sicras-MainarANavarro-ArtiedaRUse of metformin and vildagliptin for treatment of type 2 diabetes in the elderlyDrug Des Devel Ther2014818
   Web of Science ®Google Scholar
• LambertsHWoodMHofmans-OkkesÍMThe International Classification of Primary Care in the European Community With a Multi-Language LayerOxfordOxford University Press1993
   Google Scholar
• ChaffeeAYakuboffMTanabeTResponsiveness of the VAS and McGill pain questionnaire in measuring changes in musculoskeletal painJ Sport Rehabil20112025025521576715
   PubMed Web of Science ®Google Scholar
• BalonRRating scales for anxiety/anxiety disordersCurr Psychiatry Rep2007927127717880857
   PubMedGoogle Scholar
• CharlsonMEPompeiPAlesKLMackenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis1987403733833558716
   PubMedGoogle Scholar
• WeinerJPStarfieldBHSteinwachsDMMumfordLMDevelopment and application of a population-oriented measure of ambulatory care case-mixMed Care1991294524721902278
   PubMed Web of Science ®Google Scholar
• WHOThe Anatomical Therapeutic Chemical Classification System1991
   Google Scholar
• SteinerJFProchazkaAVThe assessment of refill compliance using pharmacy records: methods, validity, and applicationsJ Clin Epidemiol1997501051169048695
   PubMed Web of Science ®Google Scholar
• BennerJSGlynnRJMogunHNeumannPJWeinsteinMCAvornJLong-term persistence in use of statin therapy in elderly patientsJAMA200228845546112132975
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística 20132013 Labour Costs Survey Available from: http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736060920&menu=ultiDatos&idp=1254735976596Accessed March 1, 2014
   Google Scholar
• ThompsonSGBarberJAHow should cost data in pragmatic randomised trials be analysed?BMJ20003201197120010784550
   PubMed Web of Science ®Google Scholar
• KazisLEAndersonJJMeenanRFEffect sizes for interpreting changes in health statusMed Care198927S178S1892646488
   PubMed Web of Science ®Google Scholar
• Puig-JunoyJPolicies for pricing competition in the market of generics: lessons from the European experienceGac Sanit201024193199 Spanish20189690
   PubMed Web of Science ®Google Scholar
• Sicras MainarANavarro ArtiedaRInfluence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemiaGac Sanit20102447348220970220
   PubMed Web of Science ®Google Scholar
• HåkonsenHEilertsenMBorgeHToverudELGeneric substitution: additional challenge for adherence in hypertensive patients?Curr Med Res Opin2009252515252119708764
   PubMed Web of Science ®Google Scholar
• KesselheimASMisonoASLeeJLClinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysisJAMA20083002514252619050195
   PubMed Web of Science ®Google Scholar
• StrömOLandfeldtEThe association between automatic generic substitution and treatment persistence with oral bisphosphonatesOsteoporos Int2012232201220922120909
   PubMed Web of Science ®Google Scholar
• KesselheimASMisonoASShrankWHVariations in pill appearance of antiepileptic drugs and the risk of non-adherenceJAMA Intern Med201317320220823277164
   PubMed Web of Science ®Google Scholar
• GasserUEFischerATimmermansJPArnetIPharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar®/Prolopa®BMC Pharmacol Toxicol2013142423617953
   PubMed Web of Science ®Google Scholar
• SanderJWRyvlinPStefanHBoothDRBauerJGeneric substitution of antiepileptic drugsExpert Rev Neurother2010101887189821091318
   PubMed Web of Science ®Google Scholar
• NarayanaswamyANeogABaskaranMA randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertensionIndian J Ophthalmol20075512713117322603
   PubMedGoogle Scholar
• SteinmanMASandsLPCovinskyKESelf-restriction of medications due to cost in seniors without prescription coverageJ Gen Intern Med20011679379911903757
   PubMed Web of Science ®Google Scholar
• WeissenfeldJStockSLüngenMGerberAThe nocebo effect: a reason for patients’ non-adherence to generic substitution?Pharmazie20106545145620662309
   PubMed Web of Science ®Google Scholar
• MarkoticFCerni ObrdaljEZalihicAAdherence to pharmacological treatment of chronic nonmalignant pain in individuals aged 65 and olderPain Med20131424725623368967
   PubMed Web of Science ®Google Scholar
• TaylorSAbramowitzJSMcKayDNon-adherence and non-response in the treatment of anxiety disordersJ Anxiety Disord20122658358922440391
   PubMed Web of Science ®Google Scholar
• TranYBFrialTMillerPSStatin’s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statinsCan J Clin Pharmacol200714e205e21417556788
   PubMedGoogle Scholar